New Study: Psilocybin Shows Promise Treating Alcoholism
2.2 min readPublished On: August 25th, 2022By News Team
LOS ANGELES- A recent study has been released that further adds to the growing body of research that shows psilocybin, the hallucinogenic component found in magic mushrooms, may be an effective treatment for alcohol addiction.
Studies like this could have the potential to revolutionize addiction treatment in the coming decades. Especially important, as the United States Centers for Disease Control (CDC), has data showing alcohol abuse claims the lives of 95,000 Americans annually, reducing lifespans by an average of 26 years.
The most recent study, by researchers from New York University’s graduate school of medicine, discovered that psilocybin-assisted therapy significantly reduced heavy drinking by 83%, compared to a 51% reduction in those who got an antihistamine placebo.
Nearly half (48%) of those who had taken psilocybin stopped drinking entirely eight months following the initial dose, which is twice as many as the 24% in the placebo group.
With 93 participants, the experiment was double-blinded and sizable for a psychedelic investigation.
According to Dr. Charles Marmar, chair of psychiatry at NYU Langone Health, “today’s study is a tremendous breakthrough.”
(Dr. Charles Marmar)
He continued, “Treating alcohol abuse is extremely challenging, and the few drugs that are now available have little long-term efficacy.”
Dr. Marmar’s previous research has led to breakthroughs in our understanding of post-traumatic stress disorder (PTSD) through studies of police officers, soldiers in combat, veterans, and civilians who have been exposed to sudden, usually life-threatening events.
The trial involved 12 psychotherapy sessions spread over 12 weeks, as well as two medication-only sessions that lasted all day.
The impactful interventions came from a powerful combination of medicine combined with talk therapy.
The trial participants also started off drinking less heavily than in most studies of alcohol use disorders, according to the paper’s authors, but the study didn’t collect data after the initial 32-week observation period, so the study did not address the issue of patients potentially relapsing back into addiction.
Since the 1950’s, psychedelics have long been investigated as potential treatments for addiction. Though the trials didn’t match modern research standards, they did show promise when LSD was investigated as an alcohol addiction treatment in the 1950s and 1960s.
These more than 50 year old experiments provided the foundation upon which NYU could build their program, after decades of psychedelic research prohibition.
It’s very likely that in the next 50 years, we will see more and more use of psychedelic medicine in conjunction with traditional talk therapy and have give millions the chance to escape from addiction.
Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.
Pharmaceuticals Inc. announced today the peer-reviewed publication of its sponsored preclinical study titled "The Effect of Isolated Cannabinoid Extracts on Polypoid Colorectal Tissue" in the International Journal of Molecular Sciences; concluding "possible future therapeutic value" for the ...
LAS VEGAS, Sept. 29, 2022 Hippo Premium Packaging a provider of custom packaging and branding solutions to the cannabis and hemp industries, specializes in designing beautiful custom packaging for the cannabis and hemp industries. The ...
LANSING, Mich., Sept. 28, 2022 ACT Laboratories, Inc. a testing company in the legal cannabis and hemp markets, today announced an agreement to acquire CDX Analytics, LLC ("CDX") of Massachusetts "ACT Labs is out to build the foremost, ...
DISCLAIMER NOTE: This email should be considered strictly private and confidential. Sender of this email is not a United States Securities Dealer, nor Broker, nor U.S. Investment Adviser. Sender is a Registered Corporation and Consultant, and makes no warranties, nor representations as to the buyer, seller, or transaction. Furthermore, this email includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Read more